Insights

Is Vertex Pharmaceuticals’ Billion-Dollar Business Getting Even Bigger?

Investors have been focusing on what’s next for Vertex Pharmaceuticals (NASDAQ: VRTX) for quite a while. The company’s main business of cystic fibrosis (CF) treatments has brought in billions. But everyone wants to see the company expand beyond that specialty.
It looks like Vertex is on its way. This year, the company expects to file for regulatory approval of its treatment for blood disorders. And it has several other promising non-CF candidates in the pipeline. All this is positive. But it’s also important to take a close look at Vertex’s CF treatments — for clues about where they may be a few years down the road. Could this billion-dollar business be getting even bigger? Let’s find out.
Image source: Getty Images.

A business driving profit
First, a little background. Vertex sells four CF treatments. But the latest, Trikafta, generates the lion’s share of revenue. It brought in $1.7 billion in the first quarter. Total revenue reached $2 billion. And, importantly, this business is driving profit. The company reported a non-GAAP operating margin of 56%. And net income climbed to $762 million. That’s on a GAAP basis.
Trikafta could potentially treat 90% of all CF patients. But right now, Trikafta hasn’t reached its full audience. There are three reasons: Some countries just recently agreed to reimburse Trikafta — so patients haven’t yet started treatment. Other countries haven’t yet decided on reimbursement. And, finally, Trikafta hasn’t yet won approval in younger age groups; the company is working to expand the label to these patients. In North America, Europe, and Australia, an additional 25,000 people could benefit from Trikafta, Vertex said.
Right now, Vertex dominates the CF market. The company said in an earnings call back in 2020 that it’s set to maintain its leadership until at least the late 2030s. And in its earnings call last week, Vertex reinforced the idea by saying “we continue to strengthen our leadership for the long term.”
It’s clear Trikafta hasn’t reached its peak revenue. But Vertex isn’t relying on that treatment alone. Instead, Vertex is working on becoming its own rival. What do I mean by that? Vertex is progressing on a candidate that may be even better than Trikafta. The company’s triple combination candidate has the potential to beat Trikafta in efficacy. And its once-daily format makes it more convenient too. Patients take Trikafta twice daily in the form of three tablets. So, if anyone unseats Trikafta, it’s likely to be Vertex. Vertex expects to complete enrollment in the candidate’s phase 3 trial by the end of this year or early next year.
A second future plan
But that isn’t Vertex’s only future plan for the CF market. The company also is working on a potential treatment for the 10% of patients who aren’t candidates for its current medicines. These patients don’t produce the CFTR protein — so can’t be helped by Vertex’s drugs that aim to fix the faulty protein.
Here, Vertex has partnered with Moderna on a candidate to address that population. The idea is to program lung cells to make functional CFTR protein. The challenge has been delivering the mRNA. But the partners have made a breakthrough. They showed they could deliver CFTR mRNA in vitro — and in vivo to the bronchial epithelial cells in nonhuman primates. In the second half, the companies plan on requesting regulatory authorization to launch clinical trials for the program.
What does this mean for investors?
It’s positive that Vertex advances non-CF candidates — and broadens its business across other therapeutic areas. But it’s also important to remember that Vertex’s CF story is far from over. Instead, it continues to grow. And, even better, Vertex maintains global leadership in the field.
All of this means Vertex offers a very balanced profile: The company’s main business generates billions, and that’s set to continue well into the future. And Vertex also may be on its way to commercializing non-CF products too. Down the road, those could add to Vertex’s already strong growth.
At the same time, Vertex trades for only 28 times trailing 12-month earnings — that’s compared to about 200 back in 2018. The shares are looking pretty cheap considering all the company has to offer.
Today, Vertex is a great buy — for the potential of its pipeline and for the outlook of the blockbuster business that has powered it along so far.
Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy. –

Investors have been focusing on what’s next for Vertex Pharmaceuticals (NASDAQ: VRTX) for quite a while. The company’s main business of cystic fibrosis (CF) treatments has brought in billions. But everyone wants to see the company expand beyond that specialty.

It looks like Vertex is on its way. This year, the company expects to file for regulatory approval of its treatment for blood disorders. And it has several other promising non-CF candidates in the pipeline. All this is positive. But it’s also important to take a close look at Vertex’s CF treatments — for clues about where they may be a few years down the road. Could this billion-dollar business be getting even bigger? Let’s find out.

Image source: Getty Images.

A business driving profit

First, a little background. Vertex sells four CF treatments. But the latest, Trikafta, generates the lion’s share of revenue. It brought in $1.7 billion in the first quarter. Total revenue reached $2 billion. And, importantly, this business is driving profit. The company reported a non-GAAP operating margin of 56%. And net income climbed to $762 million. That’s on a GAAP basis.

Trikafta could potentially treat 90% of all CF patients. But right now, Trikafta hasn’t reached its full audience. There are three reasons: Some countries just recently agreed to reimburse Trikafta — so patients haven’t yet started treatment. Other countries haven’t yet decided on reimbursement. And, finally, Trikafta hasn’t yet won approval in younger age groups; the company is working to expand the label to these patients. In North America, Europe, and Australia, an additional 25,000 people could benefit from Trikafta, Vertex said.

Right now, Vertex dominates the CF market. The company said in an earnings call back in 2020 that it’s set to maintain its leadership until at least the late 2030s. And in its earnings call last week, Vertex reinforced the idea by saying “we continue to strengthen our leadership for the long term.”

It’s clear Trikafta hasn’t reached its peak revenue. But Vertex isn’t relying on that treatment alone. Instead, Vertex is working on becoming its own rival. What do I mean by that? Vertex is progressing on a candidate that may be even better than Trikafta. The company’s triple combination candidate has the potential to beat Trikafta in efficacy. And its once-daily format makes it more convenient too. Patients take Trikafta twice daily in the form of three tablets. So, if anyone unseats Trikafta, it’s likely to be Vertex. Vertex expects to complete enrollment in the candidate’s phase 3 trial by the end of this year or early next year.

A second future plan

But that isn’t Vertex’s only future plan for the CF market. The company also is working on a potential treatment for the 10% of patients who aren’t candidates for its current medicines. These patients don’t produce the CFTR protein — so can’t be helped by Vertex’s drugs that aim to fix the faulty protein.

Here, Vertex has partnered with Moderna on a candidate to address that population. The idea is to program lung cells to make functional CFTR protein. The challenge has been delivering the mRNA. But the partners have made a breakthrough. They showed they could deliver CFTR mRNA in vitro — and in vivo to the bronchial epithelial cells in nonhuman primates. In the second half, the companies plan on requesting regulatory authorization to launch clinical trials for the program.

What does this mean for investors?

It’s positive that Vertex advances non-CF candidates — and broadens its business across other therapeutic areas. But it’s also important to remember that Vertex’s CF story is far from over. Instead, it continues to grow. And, even better, Vertex maintains global leadership in the field.

All of this means Vertex offers a very balanced profile: The company’s main business generates billions, and that’s set to continue well into the future. And Vertex also may be on its way to commercializing non-CF products too. Down the road, those could add to Vertex’s already strong growth.

At the same time, Vertex trades for only 28 times trailing 12-month earnings — that’s compared to about 200 back in 2018. The shares are looking pretty cheap considering all the company has to offer.

Today, Vertex is a great buy — for the potential of its pipeline and for the outlook of the blockbuster business that has powered it along so far.

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!